+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F- Product Image
New

Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • PDF Icon

    Report

  • 185 Pages
  • February 2025
  • Region: Global
  • TechSci Research
  • ID: 5908272
Free Webex Call
10% Free customization
Description Jump to:
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Atherosclerosis Drugs Market was valued at USD 18.85 Billion in 2024, and is expected to reach USD 22.84 Billion by 2030, rising at a CAGR of 3.21%. Atherosclerosis, a condition characterized by the narrowing and hardening of arteries due to fatty plaque accumulation, continues to be a significant global health issue. It is a leading cause of heart disease, stroke, and other cardiovascular complications, resulting in millions of deaths annually. The market for atherosclerosis drugs has seen substantial growth, driven by the increasing prevalence of this condition.

Unhealthy lifestyle factors such as poor diet, physical inactivity, and smoking are major contributors to the rising incidence of atherosclerosis worldwide, leading to a large patient population in need of treatment. Furthermore, the aging global population is at higher risk, which is expected to drive demand for atherosclerosis medications. Advances in medical technology and diagnostics have enabled earlier detection, facilitating more timely interventions and treatments. Public health campaigns and increasing awareness about cardiovascular health have also encouraged more individuals to seek treatment.

While the Global Atherosclerosis Drugs Market presents significant opportunities, it also faces challenges. With the rising burden of atherosclerosis, ongoing innovation and research are critical to developing effective therapies. Personalized medicine and targeted treatments show promise in improving patient outcomes. However, challenges related to drug pricing, patient adherence, and growing competition must be addressed to ensure accessibility for those in need. The collaboration between pharmaceutical companies, healthcare providers, and policymakers will be essential to combating atherosclerosis and its impact on global health.

Key Market Drivers

Rising Prevalence of Atherosclerosis

Atherosclerosis, characterized by plaque buildup in arteries, is becoming more widespread worldwide. This condition significantly increases the risk of heart attacks, strokes, and other cardiovascular diseases, making it a global healthcare priority. As modern lifestyles contribute to obesity, hypertension, and high cholesterol, the need for effective treatments for atherosclerosis is intensifying. Diets high in saturated fats, trans fats, and processed foods, common in many regions, further exacerbate the risk factors. Additionally, atherosclerosis is more prevalent in older individuals, and as the global population ages, the incidence of this condition is expected to rise, further stressing healthcare systems. Tobacco use and diabetes are also major contributors to the increasing prevalence of atherosclerosis.

Recent research has uncovered cancer-like features in atherosclerosis, highlighting potential new treatment avenues. Studies supported by the National Institutes of Health (NIH) suggest that smooth muscle cells in arteries may take on characteristics similar to cancer cells, worsening the condition. This discovery opens the door for novel therapies, such as using anti-cancer drugs to target these tumor-like processes, offering hope for more effective treatments.

Key Market Challenges

Increasing Competition

The atherosclerosis drugs market is highly competitive, with numerous established pharmaceutical companies and emerging players vying for market share. Major pharmaceutical companies like Pfizer, AstraZeneca, and Merck have dominated the market for years, benefiting from blockbuster drugs such as Lipitor (atorvastatin) and Crestor (rosuvastatin). However, newer entrants are introducing innovative therapies and specialized drug formulations targeting different aspects of atherosclerosis treatment. These companies are focusing on niche areas such as LDL cholesterol reduction or inflammation to address unmet needs in the market.

The rise of biosimilars and generics has further intensified competition, as these cost-effective alternatives to branded drugs become more prevalent. Smaller companies or startups face challenges related to regulatory approvals, clinical trials, and securing adequate funding. The dominance of established market leaders adds to the difficulty for newcomers to differentiate themselves. To remain competitive, companies must focus on innovation, whether through new drug formulations, strategic partnerships, or acquisitions.

Key Market Trends

Technological Advancements

Technological progress in healthcare is revolutionizing the development, diagnosis, and treatment of atherosclerosis, which is contributing to the growth of the market. Modern imaging technologies such as CT angiography, MRI, and intravascular ultrasound (IVUS) provide high-resolution images of blood vessels, enabling more accurate assessment of plaque buildup and its severity. Additionally, blood tests that incorporate biomarkers like high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) aid in the early detection and risk assessment of atherosclerosis.

Artificial intelligence (AI) and machine learning are also enhancing the diagnosis of atherosclerosis by analyzing medical imaging and patient data to identify patterns and predict disease progression. These advancements are improving both the accuracy and efficiency of diagnosing atherosclerosis, contributing to better patient outcomes.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Sanofi S.A.
  • AstraZeneca Plc
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • GSK Plc

Report Scope

This report segments the Global Atherosclerosis Drugs Market into the following categories:

  • Diagnosis
  • Ankle-brachial Index
  • Doppler Ultrasound
  • Echocardiogram
  • Electrocardiogram
  • Blood Tests
  • Others
  • Treatment
  • Medication
  • Surgery
  • Others
  • Route of Administration
  • Oral
  • Parenteral
  • Others
  • End User
  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others
  • Region
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

The report includes detailed profiles of major companies in the atherosclerosis drugs market, offering insights into their market strategies and financial performance.

Available Customizations

The Global Atherosclerosis Drugs Market report can be customized to meet specific company needs, including detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Atherosclerosis Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others)
5.2.2. By Treatment (Medication, Surgery, Others)
5.2.3. By Route of Administration (Oral, Parenteral, Others)
5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others),By Region
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Atherosclerosis Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Diagnosis
6.2.2. By Treatment
6.2.3. By Route of Administration
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Atherosclerosis Drugs Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Diagnosis
6.3.1.2.2. By Treatment
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By End User
6.3.2. Canada Atherosclerosis Drugs Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Diagnosis
6.3.2.2.2. By Treatment
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By End User
6.3.3. Mexico Atherosclerosis Drugs Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Diagnosis
6.3.3.2.2. By Treatment
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By End User
7. Europe Atherosclerosis Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Diagnosis
7.2.2. By Treatment
7.2.3. By Route of Administration
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Atherosclerosis Drugs Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Diagnosis
7.3.1.2.2. By Treatment
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By End User
7.3.2. United Kingdom Atherosclerosis Drugs Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Diagnosis
7.3.2.2.2. By Treatment
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By End User
7.3.3. Italy Atherosclerosis Drugs Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Diagnosis
7.3.3.2.2. By Treatment
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By End User
7.3.4. France Atherosclerosis Drugs Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Diagnosis
7.3.4.2.2. By Treatment
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By End User
7.3.5. Spain Atherosclerosis Drugs Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Diagnosis
7.3.5.2.2. By Treatment
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By End User
8. Asia-Pacific Atherosclerosis Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Diagnosis
8.2.2. By Treatment
8.2.3. By Route of Administration
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Atherosclerosis Drugs Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Diagnosis
8.3.1.2.2. By Treatment
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By End User
8.3.2. India Atherosclerosis Drugs Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Diagnosis
8.3.2.2.2. By Treatment
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By End User
8.3.3. Japan Atherosclerosis Drugs Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Diagnosis
8.3.3.2.2. By Treatment
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By End User
8.3.4. South Korea Atherosclerosis Drugs Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Diagnosis
8.3.4.2.2. By Treatment
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By End User
8.3.5. Australia Atherosclerosis Drugs Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Diagnosis
8.3.5.2.2. By Treatment
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By End User
9. South America Atherosclerosis Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Diagnosis
9.2.2. By Treatment
9.2.3. By Route of Administration
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Atherosclerosis Drugs Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Diagnosis
9.3.1.2.2. By Treatment
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By End User
9.3.2. Argentina Atherosclerosis Drugs Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Diagnosis
9.3.2.2.2. By Treatment
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By End User
9.3.3. Colombia Atherosclerosis Drugs Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Diagnosis
9.3.3.2.2. By Treatment
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By End User
10. Middle East and Africa Atherosclerosis Drugs Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Diagnosis
10.2.2. By Treatment
10.2.3. By Route of Administration
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Atherosclerosis Drugs Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Diagnosis
10.3.1.2.2. By Treatment
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Atherosclerosis Drugs Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Diagnosis
10.3.2.2.2. By Treatment
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By End User
10.3.3. UAE Atherosclerosis Drugs Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Diagnosis
10.3.3.2.2. By Treatment
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. F. Hoffmann-La Roche Ltd
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Novartis AG
14.3. Merck & Co. Inc.
14.4. Pfizer Inc.
14.5. Eli Lilly and Co.
14.6. Sanofi S.A.
14.7. AstraZeneca Plc
14.8. Bayer AG
14.9. Regeneron Pharmaceuticals Inc.
14.10. GSK Plc
15. Strategic Recommendations16. About the Publisher & Disclaimer

Companies Mentioned

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Sanofi S.A.
  • AstraZeneca Plc
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • GSK Plc

Table Information

Report AttributeDetails
No. of Pages185
PublishedFebruary 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 18.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 22.84 Billion
Compound Annual Growth Rate3.2%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Atherosclerosis Drugs Market by Drug Class, Route of Administration, Disease Stage, Distribution Channel - Global Forecast 2025-2030 - Product Image

Atherosclerosis Drugs Market by Drug Class, Route of Administration, Disease Stage, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Atherosclerosis Drugs Market Report 2025 - Product Image

Atherosclerosis Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Atherosclerosis Drugs - Global Strategic Business Report - Product Image

Atherosclerosis Drugs - Global Strategic Business Report

  • Report
  • 389 Pages
  • Global
From
Atherosclerosis Therapeutics Market 2024-2028 - Product Image

Atherosclerosis Therapeutics Market 2024-2028

  • Report
  • 145 Pages
  • Global
From
Atherosclerosis - Pipeline Insight, 2024 - Product Image

Atherosclerosis - Pipeline Insight, 2024

  • Clinical Trials
  • 80 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.